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INTRODUCTION RESULTS
MATERIALS AND METHODS
The study is a retrospective chart review of patients who 
underwent malignant destruction of nonmelanoma skin cancer. 
CPT code searches were used to identify patients undergoing 
treatment between January 2010 and May 2013 to allow for 
sufficient length of follow up to assess recurrence rates. Method 
of destruction, tumor information (including size, location, and 
subtype), and incidence of recurrence were all extracted from 
the medical record. Patient age, sex, and immunosuppresion
status were also recorded.
Type of NMSC Number of Recurrences 
(%)
Squamous 
Cell 
Carcinoma
Low Risk:
SCCis, KA, well and moderately 
differentiated (n=428)
35 (8.18%)
High Risk:
Poorly differentiated
(n=1)
0 (0%)
Basal Cell 
Carcinoma
Low Risk:
Nodular and Superficial
(n=509)
44 (8.64%)
High Risk:
Aggressive (infiltrative or morpheaform)
(n=6)
6 (16.67%)
Figure 2: Basal cell carcinoma Table 2: Recurrence rates of nonmelanoma skin cancer based on type of malignant 
destruction
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U N I V E R S I T Y  O F  M I S S O U R I  C O L U M B I A
Megan McClean1, MD, Matthew Davis2, BS, Ryan Ladd2, BS, Calli Morris2, BS, Jesse Hirner1, MD, Nicholas Golda1, MD 
Nonmelanoma skin cancer (NMSC) is the most common 
human malignancy with estimated treatment costs of $8.1 
billion annually in the United States1.  Malignant destruction 
(MD) is one very commonly used technique for treatment of 
these malignancies.  In this study, we sought to assess 
differences in recurrence rates for NMSC treated with different 
malignant destruction techniques: electrodessication with 
curettage (EDC), cryotherapy with curettage (CC), curettage 
alone, and cryotherapy alone. 
984 tumors met our inclusion criteria. Mean follow up time was 
1,435 days (range 2-3075). We compared recurrence rates based 
on subtype of tumor and found a trend toward increased risk of 
recurrence in aggressive BCC that did not reach statistical 
significance due to small sample size in that subtype (Table 1; 
p=0.4757). No significant difference in recurrence following use of 
each of the four modalities of MD was found (Table 2; p=0.8781). 
Destructions performed on the face had a 14.08% chance of 
recurrence, which was significantly higher than destructions 
performed elsewhere (p=0.032). There was no increased risk of 
recurrence in immunosuppressed patients, and no significantly 
different risk of recurrence between genders.
This analysis demonstrates noninferiority of CC when 
compared to other methods of malignant destruction, but 
raises concern about the efficacy of malignant destruction 
as a treatment for facial NMSC.
Recurrence rates after destruction in this study fall within 
the range previously reported2,3, thus indicating these 
data may be generalizable beyond our institution.  Further, 
the analysis includes at least 20 different dermatologists; 
therefore, variations in technique from provider to provider 
are accounted for.
Figure 1: Squamous cell carcinoma
Method of destruction Number of 
Recurrences (%)
Cryotherapy alone
N=53
5 (9.43%)
Curettage alone
N=236
22 (9.32%)
Curettage with cryotherapy
N=174
10 (5.75%)
Electrodessication with Curettage
N=521
48 (9.21%)
Table 1: Recurrence rates after malignant destruction based on type of nonmelanoma skin cancer
